Organisation paid for research Program year 2025 Source: CMS Open Payments

Orthopedic Physicians Alaska

Neither a doctor nor a teaching hospital

Research payments

$1,407,551

35 payments

Through program year 2025, Orthopedic Physicians Alaska is reported as receiving $1,407,551 in research payments, across 35 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $15,910 3
2024 Research $450,339 6
2023 Research $91,617 1
2022 Research $21,604 2
2021 Research $302,360 3
2020 Research $421,326 5
2019 Research $104,395 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Horizon Therapeutics plc $935,936 10 payments
  2. Amgen Inc. $466,249 9 payments
  3. Radius Health, Inc. $5,366 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $390,985 2 payments
  2. P4 Uncontrolled Gout FORWARD II $335,527 1 payment
  3. A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $221,170 1 payment
  4. A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Ol $103,238 1 payment
  5. A Phase 4, Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $91,617 1 payment
  6. Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_168 $80,502 2 payments
  7. A Phase 4 Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $51,045 1 payment
  8. A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror [Ol]) $45,006 1 payment
  9. P4 Uncontrolled Gout AGILE $42,477 3 payments
  10. A Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Ol ) $30,145 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record